TY - JOUR
T1 - Effects of electroconvulsive therapy on the use of anxiolytics and sleep medications
T2 - a propensity score-matched analysis
AU - Tsuboi, Takashi
AU - Takaesu, Yoshikazu
AU - Hasegawa, Naomi
AU - Ochi, Shinichiro
AU - Fukumoto, Kentaro
AU - Ohi, Kazutaka
AU - Muraoka, Hiroyuki
AU - Okada, Tsuyoshi
AU - Kodaka, Funitoshi
AU - Igarashi, Shun
AU - Iida, Hitoshi
AU - Kashiwagi, Hiroko
AU - Hori, Hikaru
AU - Ichihashi, Kayo
AU - Ogasawara, Kazuyoshi
AU - Hashimoto, Naoki
AU - Iga, Jun ichi
AU - Nakamura, Toshinori
AU - Usami, Masahide
AU - Nagasawa, Tatsuya
AU - Kido, Mikio
AU - Komatsu, Hiroshi
AU - Yamagata, Hirotaka
AU - Atake, Kiyokazu
AU - Furihata, Ryuji
AU - Kikuchi, Saya
AU - Horai, Tadasu
AU - Takeshima, Masahiro
AU - Hirano, Yoji
AU - Makinodan, Manabu
AU - Matsumoto, Junya
AU - Miura, Kenichiro
AU - Hishimoto, Akitoyo
AU - Numata, Shusuke
AU - Yamada, Hisashi
AU - Yasui-Furukori, Norio
AU - Inada, Ken
AU - Watanabe, Koichiro
AU - Hashimoto, Ryota
N1 - Funding Information:
This study was supported by the Japan Agency for Medical Research and Development (AMED) under Grant Number JP16dk0307060, JP19dk0307083, and JP22dk0307112, the Health and Labor Sciences Research Grants (H29‐Seishin‐Ippan‐001, 19GC1201), the Japanese Society of Neuropsychopharmacology, the Japanese Society of Mood Disorders and the Japanese Society of Clinical Neuro‐psychopharmacology. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Publisher Copyright:
© 2022 The Authors. Psychiatry and Clinical Neurosciences © 2022 Japanese Society of Psychiatry and Neurology.
PY - 2023/1
Y1 - 2023/1
N2 - Aim: We investigated the association of electroconvulsive therapy (ECT) with anxiolytic and sleep medication use in patients with major depressive disorder (MDD) and schizophrenia (SZ). Methods: This nationwide observational study analyzed data from 3483 MDD inpatients and 6663 SZ inpatients. Patients with MDD and SZ were classified into those who underwent ECT during hospitalization and those who did not. A propensity score-matching method was performed to adjust for preadmission characteristics and clinical information, which were expected bias between the two groups. Rates of anxiolytic and sleep medication use at discharge were compared in the matched sample. Results: 500 MDD patients were assigned to both groups. In the matched MDD sample, the rate of anxiolytic and sleep medication use at discharge was significantly lower in the ECT group than in the non-ECT group (64.9% vs. 75.8%, P = 1.7 × 10−4). In the ECT group, the rate of anxiolytic and sleep medication use at discharge was significantly lower than that prior to admission (64.9% vs. 73.2%, P = 1.2 × 10−14). 390 SZ patients were allocated. In the matched SZ sample, the ECT group was not significantly different from the non-ECT group in the rate of anxiolytics and sleep medications use at discharge (61.3% vs. 68.2%, P = 4.3 × 10−2). In the ECT group, the rate of anxiolytics and sleep medications use at discharge was significantly lower than that before admission (61.3% vs. 70.5%, P = 4.4 × 10−4), although this was not the primary outcome. Conclusion: Reduction of anxiolytic and sleep medication use may be considered positively when ECT is indicated for treatment of MDD.
AB - Aim: We investigated the association of electroconvulsive therapy (ECT) with anxiolytic and sleep medication use in patients with major depressive disorder (MDD) and schizophrenia (SZ). Methods: This nationwide observational study analyzed data from 3483 MDD inpatients and 6663 SZ inpatients. Patients with MDD and SZ were classified into those who underwent ECT during hospitalization and those who did not. A propensity score-matching method was performed to adjust for preadmission characteristics and clinical information, which were expected bias between the two groups. Rates of anxiolytic and sleep medication use at discharge were compared in the matched sample. Results: 500 MDD patients were assigned to both groups. In the matched MDD sample, the rate of anxiolytic and sleep medication use at discharge was significantly lower in the ECT group than in the non-ECT group (64.9% vs. 75.8%, P = 1.7 × 10−4). In the ECT group, the rate of anxiolytic and sleep medication use at discharge was significantly lower than that prior to admission (64.9% vs. 73.2%, P = 1.2 × 10−14). 390 SZ patients were allocated. In the matched SZ sample, the ECT group was not significantly different from the non-ECT group in the rate of anxiolytics and sleep medications use at discharge (61.3% vs. 68.2%, P = 4.3 × 10−2). In the ECT group, the rate of anxiolytics and sleep medications use at discharge was significantly lower than that before admission (61.3% vs. 70.5%, P = 4.4 × 10−4), although this was not the primary outcome. Conclusion: Reduction of anxiolytic and sleep medication use may be considered positively when ECT is indicated for treatment of MDD.
UR - http://www.scopus.com/inward/record.url?scp=85145492511&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85145492511&partnerID=8YFLogxK
U2 - 10.1111/pcn.13489
DO - 10.1111/pcn.13489
M3 - Article
C2 - 36215112
AN - SCOPUS:85145492511
SN - 1323-1316
VL - 77
SP - 30
EP - 37
JO - Psychiatry and clinical neurosciences
JF - Psychiatry and clinical neurosciences
IS - 1
ER -
